Ask AI
ProCE Banner Activity

Personalizing Treatment of HER2-Positive Advanced Bladder Cancer: Expert Guidance on the Latest Evidence for HER2-Targeted ADCs

Slideset

Download these slides from a recent educational program to enhance your approach to HER2-positive advanced bladder cancer care by exploring the latest evidence and practical strategies. Gain expert insights on HER2-targeted ADCs, molecular testing, treatment sequencing, and adverse event management.

Released: February 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity has been designed to meet the educational needs of oncologists, urologists, pathologists, and other healthcare professionals who care for patients with bladder cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Perform molecular testing and interpretation concordant with expert recommendations to identify patients with advanced bladder cancer who are most likely to benefit from established or emerging HER2-targeted ADCs

  • Evaluate the potential clinical implications of emerging data for novel HER2-targeted ADCs on management of HER2-positive advanced bladder cancer

  • Plan individualized treatment sequences leveraging HER2-targeted ADCs for eligible patients with advanced bladder cancer based on the latest evidence, guidelines, and patient/disease factors

  • Develop strategies to anticipate, monitor, and manage AEs associated with HER2-targeted ADCs in patients with advanced bladder cancer